• 901.348.5774
  • EMAIL US
  • PAYMENT
  • PORTAL

Stop Cancer Where It Starts

Through genomic research, we continue to learn more about the complexity of cancer. While cancer continues to be identified by its location in the body (lung, breast, blood, etc.), we have learned that a more accurate way to evaluate cancer is through examination of the underlying changes or mutations which drive cancer development and progression. Those mutations are not limited to location and, in many instances, have very little correlation with the location.  Understanding the core genetic mutations which drive cancer progression allows clinicians to replace more traditional treatments with newer, less toxic, therapies that target those specific mutations. 

GenOnc Panel 1 - ACTIONABLE  (8 Genes)

Targets key regions of 8 genes identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO) to be clinically actionable somatic mutations in solid tumors

GenOnc Panel 2 - CLINICALLY RELEVANT   (24 Genes)

Targets clinically relevant mutations in these genes have been identified by guidelines and published opinions from groups such as the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO)

GenOnc Panel 3 – COMPREHENSIVE (275 genes)

The GenOnc Comprehensive Cancer Panel is the most comprehensive cancer gene panel available. Encompassing over 50% of the Welcome Trust Sanger Institute Cancer Gene Census, this 409 gene panel targets key tumor suppressor genes and oncogenes that are the most frequently cited and most frequently mutated in cancer. The panel includes genes that function in growth factor and cytokine responses, signaling cascades, apoptosis, DNA repair, cell cycle regulation, transcription regulation, and inflammatory response pathways

GenOnc Panel 4 - PREDISPOSITION   (143 genes)

Predisposition Targeted Panel is a multiplexed PCR-based assay for targeted enrichment of the coding (exonic) regions of the 143 genes commonly mutated in 88 inherited oncogenic diseases